Why is Alignment Healthcare stock tumbling today?

Alignment Healthcare LLC shares plummeted 21.4% in after-hours trading following the Centers for Medicare & Medicaid Services' release of the 2027 Medicare Advantage Star Ratings. The company's crucial California H3815 HMO contract had received a downgrade from 4.0 stars to 3.5 stars, which impacts roughly 75% of its total membership and jeopardizes federal quality bonus payments for the fiscal year 2028.

Alignment Healthcare acknowledged the downgrade in a press release, attributing it to higher industry cut points, weaker performance in certain triple-weighted clinical measures, and the retroactive elimination of bonus calculations linked to a health equity index. The company has pledged to contest the ratings methodology through administrative appeals and litigation, expressing confidence in regaining at least a 4-star rating in future years.

However, Barclays had lowered its price target on the stock from $16 to $10 the previous day, maintaining an Equal Weight rating, which had already established a cautious atmosphere before the CMS release. This outcome created a significant disparity within the Medicare Advantage sector, with Humana, a competitor in the government-backed health plan industry, experiencing a significant 4-star rating upgrade for one of its primary contracts in the same CMS release, which boosted its shares sharply.

The contrast between the two firms' ratings heightened the selling pressure on ALHC. The CMS downgrade of Alignment's flagship California contract, which covers most of its members, along with the pre-existing Barclays price target reduction and the stark difference with a competitor's rating upgrade, formed a potent combination of negative factors that drove the stock to a new area near its 52-week low of $7.37, erasing a substantial portion of its market value in just one after-hours session.